P-100Efficacy, safety, and pharmacokinetics of the anti-programmed cell death receptor-1 (PD-1) monoclonal antibody, tislelizumab (BGB-A317) in a phase 2, open-label, multicenter study to investigate in patients with unresectable hepatocellular carcinoma - Trial in progress. (20th June 2018)

Record Type:: Journal Article
Title:: P-100Efficacy, safety, and pharmacokinetics of the anti-programmed cell death receptor-1 (PD-1) monoclonal antibody, tislelizumab (BGB-A317) in a phase 2, open-label, multicenter study to investigate in patients with unresectable hepatocellular carcinoma - Trial in progress. (20th June 2018)
Main Title:: P-100Efficacy, safety, and pharmacokinetics of the anti-programmed cell death receptor-1 (PD-1) monoclonal antibody, tislelizumab (BGB-A317) in a phase 2, open-label, multicenter study to investigate in patients with unresectable hepatocellular carcinoma - Trial in progress
Authors:: Cheng, A
Abou-Alfa, G
Ren, Z
Assenat, E
Cubillo, A
Pluntke, S
Rimassa, L
Ross, P
Wyrwicz, L
Hou, J
Li, C
Wu, J
Ducreux, M
Abstract:
Is Part Of:: Annals of oncology. Volume 29(2018)Supplement 5
Journal:: Annals of oncology
Issue:: Volume 29(2018)Supplement 5
Issue Display:: Volume 29, Issue 5 (2018)
Year:: 2018
Volume:: 29
Issue:: 5
Issue Sort Value:: 2018-0029-0005-0000
Page Start:
Page End:
Publication Date:: 2018-06-20
Subjects:: Oncology -- Periodicals
616.992
Journal URLs:: https://www.journals.elsevier.com/annals-of-oncology ↗
http://ukcatalogue.oup.com/ ↗
DOI:: 10.1093/annonc/mdy151.099 ↗
Languages:: English
ISSNs:: 0923-7534
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 1043.320000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 12263.xml